Image Sourced ShutterStock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • RotoGro is expanding its global presence following the purchase of Canadian company Supra THC and the distribution of its ‘Garden’ technology across North America, Europe and Australasia
  • RotoGro’s share price hasn’t changed from previous close. It currently sits at $0.15 per share.

RotoGro is focusing on increasing its global presence as a cultivator of legal cannabis.

Following the purchase of Canadian medical cannabis testers, Supra THC, the company is looking to expand its business.

Supra THC obtained a dealers license from Health Canada. The license gives the company approval to conduct standard processing, analytical testing, research, production and sales and distribution of lawful cannabis.

As RotoGro works to increase its presence in Canada, the company is looking at becoming dually listed on the Canadian Securities Exchange (CSE).

In addition the being listed on the ASX, RotoGro is also listed on Germany’s Frankfurt Stock Exchange.

According to the company, being listed on the CSE exposes it to the largest capital market for cannabis focused companies globally.

RotoGro’s Garden technology has been successful in reducing operation costs and improving product consistency.

The tech triples growing space while occupying the same space as a regular flat deck table, significantly increasing the amount of cannabis grown in a given time frame.

RotoGro receive revenue from selling its Garden technology to other companies growing cannabis and agricultural businesses.

The company’s technology is being delivered across North America, Europe and Australasia.

RotoGro’s share price hasn’t changed from previous close. It currently sits at $0.15 per share.

RGI by the numbers
More From The Market Online

Recce breathes better on positive lung infection drug pilot test results

Recce Pharmaceuticals Ltd has revealed positive results from its pilot test on synthetic drug Recce 327,…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Botanix isn’t sweating on FDA approval for Sofdra

Botanix has submitted the last label materials to the FDA seeking approval for Sofdra™ a prescription…

Singular Health launches upgraded DICOM viewer, with patient-friendly features for engagement with medical records

Singular Health Ltd has launched an upgraded version of its DICOM viewer, set to allow greater…